329206-31-7 Usage
Explanation
The compound consists of 24 carbon atoms, 26 hydrogen atoms, 2 chlorine atoms, 2 nitrogen atoms, and 2 oxygen atoms.
Explanation
The compound has a tricyclic ring system with a fusion of five-, four-, and nine-membered rings, according to the given notation.
Explanation
The compound contains two nitrogen atoms located at the 2 and 10 positions in the structure.
Explanation
A 2,4-dichlorophenyl group is attached to the tricyclic ring system at the 9 position.
Explanation
The compound has multiple double bonds in its structure, as indicated by the "tetraen" part of the name.
Explanation
A ketone functional group is present at the 7 position of the tricyclic ring system.
8. Unique and specific chemical properties
Explanation
Due to the complex structure of the compound, it is expected to have unique and specific chemical properties that may require further analysis and research to fully understand.
9. Potential uses and effects
Explanation
The specific uses and effects of 2,10-DIAZA-9-(2,4-DICHLOROPHENYL)-5,5-DIMETHYLTRICYCLO[9.4.0.0(3,8)]PENTADECA-1(11),3(8),12,14-TETRAEN-7-ONE are not yet known and would require further investigation to determine.
Tricyclic ring structure
9.4.0.0(3,8)pentadeca
Presence of two nitrogen atoms
2,10-diaza
2,4-dichlorophenyl group
9-(2,4-dichlorophenyl)
Double bonds
tetraen
Methyl groups
5,5-dimethyl
Ketone group
7-one
Check Digit Verification of cas no
The CAS Registry Mumber 329206-31-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,9,2,0 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 329206-31:
(8*3)+(7*2)+(6*9)+(5*2)+(4*0)+(3*6)+(2*3)+(1*1)=127
127 % 10 = 7
So 329206-31-7 is a valid CAS Registry Number.
329206-31-7Relevant academic research and scientific papers
BENZODIAZEPINES AS HCV INHIBITORS
-
Page/Page column 54; 111, (2008/06/13)
The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates Io benzodiazepine compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
